AGM/EGMJun 8, 2026, 04:22 PM
Avalo Therapeutics Stockholders Approve ESPP, Elect Directors
AI Summary
Avalo Therapeutics held its 2026 Annual Meeting of Stockholders on June 2, 2026. Stockholders approved the election of seven directors to the Board and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, the Second Amended and Restated 2016 Employee Stock Purchase Plan was approved.
Key Highlights
- Stockholders elected seven nominees to the Board of Directors.
- The Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan was approved with 14,513,683 votes For.
- Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 with 22,513,332 votes For.
- Approximately 85% of outstanding shares (22,672,284 shares) were present or represented by proxy at the Annual Meeting.
Price Impact
More from AVTX